Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech/OSI Raise Tarceva Price 15% In Wake Of Iressa Failure

This article was originally published in The Pink Sheet Daily

You may also be interested in...



Oncology Sales Drive Strong Quarter For Genentech

Avastin and Herceptin were each up more than 70% over the prior year’s quarter.

Oncology Sales Drive Strong Quarter For Genentech

Avastin and Herceptin were each up more than 70% over the prior year’s quarter.

Iressa Survival Data Adequately Disseminated To Physicians/Patients, Cmte. Says

AstraZeneca communication to physicians/patients on Iressa survival data has been adequate, FDA Oncologic Drugs Advisory Committee says. FDA asks committee to discuss possibility of recommending Genentech/OSI Pharma’s Tarceva as alternative to Iressa in labeling, but committee resists.

Related Content

Topics

UsernamePublicRestriction

Register

PS061969

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel